ABNX — Abionyx Pharma SA Income Statement
0.000.00%
Last trade - 00:00
- €30.16m
- €32.53m
- €5.25m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.174 | 0 | 0 | 0.675 | 5.25 |
Cost of Revenue | |||||
Gross Profit | 0.174 | 0 | 0 | 0.259 | 0.636 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 7.23 | 2.52 | 2.97 | 6.63 | 9.36 |
Operating Profit | -7.05 | -2.52 | -2.97 | -5.95 | -4.11 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.3 | 1.89 | -1.89 | -5.82 | -4.21 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6.31 | 1.85 | -1.89 | -5.82 | -4.21 |
Net Income Before Extraordinary Items | |||||
Net Income | -6.31 | 1.85 | -1.89 | -5.82 | -4.21 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.3 | 1.85 | -1.89 | -5.82 | -4.21 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.339 | 0.088 | -0.084 | -0.234 | -0.15 |
Dividends per Share |